PMV Pharmaceuticals, Inc
PMVP · United States
Share price · PMVP
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when PMVP's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 26 Oct 2026-11.0%
Nothing announced by PMVP that day or the session before.
- 30 Sep 2026+16.8%
Nothing announced by PMVP that day or the session before.
- 14 Jul 2026+10.9%
Nothing announced by PMVP that day or the session before.
- 15 Jun 2026-4.5%
Nothing announced by PMVP that day or the session before.
- 27 Feb 2026+24.1%
- 26 Feb 2026+22.3%
- 10 Feb 2026+6.4%
Nothing announced by PMVP that day or the session before.
- 29 Jan 2026-8.2%
Nothing announced by PMVP that day or the session before.
- 18 Dec 2025+8.8%
Nothing announced by PMVP that day or the session before.
- 9 Dec 2025+6.0%
Nothing announced by PMVP that day or the session before.
Share of unusual movement by asset
For each asset, the share of PMVP's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
Assets
(1 total)
| Target & Modality | |||
|---|---|---|---|
| Phase 1/2 | p53 reactivatorSmall molecule | Non-Small Cell Lung CancerBreast CancerOvarian Cancer HR+/HER2- Metastatic Breast Cancer |
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2026 (1)
December 2026 (1)
What to watch
Regulatory and conference events
(2)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
Financial reports
Quarterly & interim (16)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | — | $16M | $20M+ $83M short-term inv. | $34M-$18M operating cash flow | report ↗ |
View 15 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | — | $15M | $12M+ $67M short-term inv. | $18M-$15M operating cash flow | report ↗ |
| 2026-Q1 | — | $15M | $39M+ $54M short-term inv. | $18M-$20M operating cash flow | report ↗ |
| 2025-Q3 | — | $18M | $36M+ $93M short-term inv. | $21M-$20M operating cash flow | report ↗ |
| 2025-Q2 | — | $18M | $44M+ $98M short-term inv. | $21M-$18M operating cash flow | report ↗ |
| 2025-Q1 | — | $17M | $51M+ $109M short-term inv. | $17M-$18M operating cash flow | report ↗ |
| 2024-Q3 | — | $17M | $49M+ $134M short-term inv. | $19M-$17M operating cash flow | report ↗ |
| 2024-Q2 | — | $15M | $49M+ $164M short-term inv. | $1.2M-$1.6M operating cash flow | report ↗ |
| 2024-Q1 | — | $13M | $48M+ $150M short-term inv. | $15M-$16M operating cash flow | report ↗ |
| 2023-Q3 | — | $14M | $52M+ $150M short-term inv. | $17M-$16M operating cash flow | report ↗ |
| 2023-Q2 | — | $14M | $68M+ $119M short-term inv. | $17M-$13M operating cash flow | report ↗ |
| 2023-Q1 | — | $15M | $143M+ $86M short-term inv. | $19M-$15M operating cash flow | report ↗ |
| 2022-Q3 | — | $14M | $100M+ $159M short-term inv. | $18M-$17M operating cash flow | report ↗ |
| 2022-Q2 | — | $11M | $87M+ $190M short-term inv. | $17M-$14M operating cash flow | report ↗ |
| 2022-Q1 | — | $12M | $116M+ $167M short-term inv. | $18M-$18M operating cash flow | report ↗ |
| 2021-Q3 | — | $9.2M | $177M+ $131M short-term inv. | $15M-$12M operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | — | $70M | $38M+ $75M short-term inv. | $19M-$74M operating cash flow | report ↗ |
PMV Pharmaceuticals reported no revenue for the full year ended December 31, 2025. R&D expenses were $69.9M, up 19.4% YoY from $58.5M, while the company posted a net loss of $77.7M, compared with $58.7M in 2024. Cash, cash equivalents, and marketable securities totaled $112.9M at year-end, with an expected cash runway into the end of the second quarter of 2027.
Management guided to a New Drug Application submission for rezatapopt in platinum-resistant/refractory ovarian cancer in the first quarter of 2027, with enrollment on track in the pivotal Phase 2 portion of the PYNNACLE trial. Key developments included FDA Orphan Drug Designation for rezatapopt in TP53 Y220C-positive ovarian cancer, publication of first-in-human data in the New England Journal of Medicine, and updated PYNNACLE results showing a 34% overall response rate across all cohorts and a 46% ORR in the ovarian cancer cohort at the September 4, 2025 data cutoff.
View 4 more years
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-FY | — | $59M | $41M+ $129M short-term inv. | $15M-$51M operating cash flow | report ↗ |
| 2023-FY | — | $56M | $38M+ $165M short-term inv. | $17M-$56M operating cash flow | report ↗ |
| 2022-FY | — | $52M | $108M+ $133M short-term inv. | $18M-$64M operating cash flow | report ↗ |
| 2021-FY | — | $36M | $172M+ $125M short-term inv. | $14M-$47M operating cash flow | report ↗ |
Insider transactions
Open-market activity, trailing 12 months: 0 purchases (—), 0 sales (—). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-10-01 | Eckler Matthew Joseph · director | Award / grant (derivative) | 84,000 | — | — | Form 4 |
| 2026-06-04 | BAUM CHARLES M · director | Award / grant (derivative) | 42,000 | — | — | Form 4 |
| 2026-06-04 | FLOWERS KIRSTEN · director | Award / grant (derivative) | 42,000 | — | — | Form 4 |
| 2026-06-04 | Gallagher Carol Giltner · director | Award / grant (derivative) | 42,000 | — | — | Form 4 |
| 2026-06-04 | LEVINE ARNOLD J · director | Award / grant (derivative) | 42,000 | — | — | Form 4 |
| 2026-06-04 | Stelzer Laurie · director | Award / grant (derivative) | 42,000 | — | — | Form 4 |
| 2026-06-04 | Gallagher Carol Giltner · director | Gift (derivative) | 42,000 | — | — | Form 4 |
| 2026-06-04 | Gallagher Carol Giltner · director | Gift (derivative) | 42,000 | — | — | Form 4 |
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 69 reporting institutions held 37.0M shares ($43.0M, 48.9% of shares outstanding).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | BML Capital Management, LLC | 5,320,000 | $6.6M |
| 2 | TANG CAPITAL MANAGEMENT LLC | 4,245,085 | $5.3M |
| 3 | Sio Capital Management, LLC | 3,076,580 | $3.8M |
| 4 | ArrowMark Colorado Holdings LLC | 2,872,764 | $3.6M |
| 5 | Euclidean Capital LLC | 2,627,643 | $3.3M |
| 6 | Eversept Partners, LP | 2,348,360 | $2.9M |
| 7 | VANGUARD CAPITAL MANAGEMENT LLC | 1,974,906 | $2.4M |
| 8 | TWO SIGMA INVESTMENTS, LP | 1,884,530 | $2.3M |
| 9 | ADAGE CAPITAL PARTNERS GP, L.L.C. | 1,860,000 | $2.3M |
| 10 | BlackRock, Inc. | 874,374 | $1.1M |
| 11 | MORGAN STANLEY | 864,311 | $1.1M |
| 12 | Stonepine Capital Management, LLC | 708,102 | $878K |
| 13 | Longaeva Partners L.P. | 552,027 | $685K |
| 14 | GEODE CAPITAL MANAGEMENT, LLC | 495,922 | $615K |
| 15 | Aldebaran Capital, LLC | 473,362 | $587K |